1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Executive Decisions Roundup

ORA strategic deputy sought, CHPA names Brian Green CFO and Alternaturals’ leadership shake up continues.

FDA’s field organization is seeking to fill a new position for a deputy associate commissioner for regulatory affairs strategic management. The new deputy associate commissioner will lead all ORA strategic management duties, as well as oversee about 350 FTEs that are “engaged in activities designed to optimize the use of FDA’s field resources,” according to the job notice. That includes designing “risk-based resource allocation and priority setting systems” and a new multi-year field work-planning process, as well as formulating a budget that combines “the needs of the ORA organization with the needs of the product centers needing ORA expertise,” according to the job notice. The position, which reports to Melinda Plaisier, FDA’s associate commissioner for regulatory affairs, also will oversee all day-to-day management issues and provide overall organization management to improve office performance, according to the notice.

The Consumer Healthcare Products Association expands its senior management team with Brian Green as VP of finance and operations and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

More from North America

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.